Earnings
Home›Earnings›Analyst Ratings›Arrowhead drug REDEMPLO expands in Germany after Q3 su…
Arrowhead drug REDEMPLO expands in Germany after Q3 surge
Arrowhead reported Q3 2026 revenue up 171% year over year to $75.3 million and said REDEMPLO U.S. prescriptions doubled, while a European authorization in June 2026 enabled the Germany launch listing in the Lauer-Taxe database.
Arrowhead Pharmaceuticals’ REDEMPLO reached a European milestone after the company said it became available in Germany for adults with Familial Chylomicronemia Syndrome. The drug’s availability followed European Commission authorization in June 2026, and it was listed in Germany’s Lauer-Taxe database for prescribing and reimbursement.
The article says REDEMPLO can be prescribed once every three months based on clinical symptoms or genetic tests, rather than requiring genetic confirmation, and that the German expansion came shortly after Arrowhead reported its fiscal third quarter 2026 results on August 4.
According to the piece, Arrowhead’s quarterly revenue rose 171% year over year to $75.3 million, above Wall Street’s $52.7 million expectation, driven by collaboration income and doubled REDEMPLO U.S. prescription volume. The company’s net loss attributable to it widened to $194.2 million, or $1.36 per share, while total cash resources were cited at $1.56 billion.
The article also notes that H.C. Wainwright raised its price target for Arrowhead to $120 from $115 and reiterated a Buy rating. It cited a one quarter pull forward in the plozasiran launch timeline for severe hypertriglyceridemia and a new partnership with Madrigal, along with the impact of positive SHASTA 3 and SHASTA 4 data and the company’s stated liquidity to fund late stage programs.